On the morning of September 28, 2023, the listing ceremony of Shanghai Wuxin Medical Technology Group Co., Ltée. (stock abbreviation: Wuxin Shares, stock code: 300543) was grandly held at the Shanghai Equity Exchange Center.
Attendees of the listing ceremony included: Mr. Bu Qigang, Chairman of Zhujiajiao Industrial Park in Qingpu District, Shanghai; Mr. Jiang Changming, Deputy Director of the Civil Affairs Bureau of Sanming City, Fujian Province; Mr. Su Dingfeng, Foreign Academician of the French Academy of Pharmacy, Chief Scientist of China’s 973 Program, and Leader of a National Key Discipline; Mr. Wu Ruihai, Academician of the French National Academy of Sciences, former private physician to the President of France, and the world’s first brain cell transplantation expert; Mr. Zhu Naishuo, Final Review Judge of the National 863 Biomedical High Technology Program, Chairman of the Immunogenetics Professional Committee of the Shanghai Immunology Society, and Executive Director of the Fudan Medical Cell Rehabilitation Joint Center; General Ye Zhisheng, former Chief of Staff of the Shanghai Garrison Command; Mr. Wan Jun, Director of the China High-Tech Industrialization Research Association; Mr. Yang Xun’er, President of the Hong Kong Kong Hai Buddhist Confucianism Joint Research Association; Ms. Zhuang Jinlian, President of the Sanming Elderly Care Federation of Fujian Province; Mr. Zheng Guohong, Chairman of Gaobo Aviation Technology (Shanghai) Co., Ltd.; Ms. Fang Mei, President of the Baoji City Women Entrepreneurs Association in Shaanxi Province, along with shareholders and guests who witnessed the ceremony together.
Wuxin Shares actively implements technological innovation policies, strengthens corporate governance, and enhances transparency in information disclosure. The successful listing not only reflects the capital market’s recognition of the company but also provides more opportunities for its future development. This listing marks an important milestone in the company’s development journey, symbolizing its readiness to face the future with a new posture.
Wuxin Shares is a high-tech company focusing on the R&D, application, and comprehensive health management services in the field of cell biology. It is one of the earliest research-oriented enterprises in China engaged in cell biology research and has achieved numerous results. In 2022, the company, as a key industrial project of the Qingpu District People’s Government of Shanghai, settled in the Yangtze River Delta Integration Demonstration Zone – Zhujiajiao Industrial Park. The company is building a headquarters industrial base centered on regenerative medicine and aimed at developing cell biological drugs, covering business areas such as stem cell regenerative medicine, precision medicine, and health management combining medical care and elderly care.
The company’s core technology leaders include senior academicians and experts like Su Dingfeng, Wu Ruihai, and Zhu Naishuo, who have numerous advanced scientific research achievements domestically. In 2022, Wuxin Group signed a joint scientific research cooperation agreement with Fudan University, establishing a market transformation base for university research achievements, propelling the company onto a fast track of industrial development. The successful listing on the Shanghai Equity Exchange Center holds significant strategic importance for Wuxin Group. According to the group’s development plan, with the support of capital, Wuxin Group will leverage its advantages in expert talent and advanced research and technology to create a benchmark for regenerative medicine and life science industries at its project site, thereby driving the development of health and beauty industries. This will provide a new channel for public health care, contribute to local economic development, and create more jobs and tax revenue.
Let us sincerely wish Wuxin Group continued success and more valuable contributions to society.
